Department of Defense’s Mandatory Testosterone Screening Program: A Deep Dive into Potential Unintended Consequences
The Department of Defense’s recent announcement of a mandatory testosterone screening program for service members, particularly those aged 30 and over, has ignited a complex discussion among medical professionals and public health experts. While the stated intention is to prioritize the health and readiness of U.S. servicemembers, the rollout of such a large-scale screening initiative for a hormone with multifaceted implications carries the potential for significant and unforeseen consequences. As a practicing urologist and health outcomes researcher with extensive experience studying men’s health and population-level screening, particularly within military populations, I believe a thorough examination of the risks and benefits is not just prudent, but essential.
The surge in interest surrounding testosterone supplementation in recent years has been considerable, often outpacing our collective scientific and medical understanding of testosterone deficiency and its optimal management. This growing public fascination, fueled by direct-to-consumer marketing, online wellness communities, and influencer endorsements, has transformed the testosterone therapy market into a multi-billion dollar global industry. Annual sales, which were a modest $18 million in the late 1980s, are projected to reach nearly $2 billion by 2025, reflecting a dramatic escalation in demand and prescription rates. This unprecedented expansion necessitates a careful evaluation, especially when considering its application within a uniformed military force, where decisions about health directly impact operational readiness and national security.
Understanding Testosterone: More Than Just a Sex Hormone
Testosterone, a primary male sex hormone, plays a critical role in a complex endocrine system known as the hypothalamic-pituitary-gonadal (HPG) axis. This intricate network orchestrates crucial developmental processes, including the formation of male reproductive organs in utero, the dramatic changes experienced during puberty, and the regulation of various physiological functions throughout a man’s life. Beyond its reproductive roles, testosterone is associated with certain behavioral characteristics, including aggression and libido, and influences muscle mass, bone density, and even mood.
The natural decline in testosterone levels with age is a well-documented phenomenon. Many symptoms commonly associated with aging, such as increased body fat, reduced bone density (osteoporosis), and decreased libido, can also be observed in conditions where the HPG axis is disrupted. Factors such as obesity, sedentary lifestyles, and certain dietary patterns can further contribute to lower testosterone levels, creating a complex interplay of influences on hormonal balance. This has led to a legitimate interest within the medical community in exploring testosterone supplementation as a potential strategy to mitigate some effects of aging and enhance energy levels in older men.
The Rise of Testosterone Therapy and its Shifting Landscape
The growing interest in testosterone therapy has extended beyond addressing age-related declines. A significant portion of the recent market expansion has been driven by middle-aged and older men who exhibit testosterone levels below the reference ranges established for younger men, even in the absence of diagnosed disorders of the HPG axis. While many individuals using these therapies are managed appropriately, a concerning trend has emerged where some obtain testosterone through loosely regulated online channels. This can result in the administration of supranormal and potentially unsafe levels of the hormone, bypassing standard medical oversight.
The potential benefits of testosterone replacement therapy (TRT) are recognized: it can indeed increase muscle mass, enhance libido, and in some cases, lead to mood and behavioral changes that some men find desirable. However, the medical community has grappled with the inherent risks associated with TRT, a landscape that has seen evolving research and sometimes conflicting findings.
Evolving Research on Cardiovascular Risks
Early concerns regarding the cardiovascular safety of TRT were highlighted by the Testosterone in Older Men with Mobility Limitations (TOM) study in 2010. This trial was prematurely halted due to a statistically significant higher incidence of major cardiac events, including heart attacks and strokes, among participants receiving testosterone replacement therapy.
More recently, the Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men (TRAVERSE) trial, published in 2023, provided a more nuanced perspective. While the TRAVERSE trial did not replicate the increased risk of adverse cardiac events observed in the TOM study, suggesting TRT was no worse than placebo in this regard, it did identify a higher incidence of other serious adverse events. These included acute kidney injury, atrial fibrillation, and pulmonary embolism in men undergoing testosterone therapy.
Military-Specific Health Outcomes and Concerns
Research conducted within military populations has also shed light on the health outcomes associated with TRT. My own research group, as part of an effort to evaluate health outcomes for servicemembers covered by TRICARE, the military’s health insurance program, has examined the side effects of testosterone replacement. These DOD-supported studies revealed higher rates of kidney stones and obstructive sleep apnea among military beneficiaries who used testosterone supplementation. While one of these studies did indicate a significant improvement in cardiovascular disease outcomes, the findings underscore the importance of a comprehensive risk-benefit analysis tailored to the specific physiological and lifestyle demands of military service.
Critical Considerations for the DoD’s Screening Program
The Department of Defense’s directive to screen service members aged 30 and over raises several critical considerations, particularly concerning fertility and the potential for adverse effects in younger individuals. Testosterone replacement therapy is known to reduce testicular size and sperm counts. Both the American Urological Association and the Endocrine Society guidelines strongly caution against testosterone usage in men who intend to have children, due to its significant impact on fertility. This aspect is of paramount importance for a military population that may include individuals in their reproductive years.
Furthermore, the accurate measurement and interpretation of testosterone levels are complex. Testosterone levels are influenced by numerous factors and are subject to diurnal variations. Standard medical practice dictates that measurements should be taken at specific times of the day, ideally in the morning, and often require a second confirmatory test. Diagnosis of hypogonadism, or low testosterone, should also be made in conjunction with other clinical markers, including complete blood counts and other hormone levels, to identify potential underlying causes and rule out confounding conditions.
Before initiating testosterone replacement, individuals must undergo thorough screening for conditions that could be exacerbated by TRT. These include sleep apnea, a high risk for prostate cancer, pre-existing heart failure or heart disease, and conditions associated with thrombophilia, such as elevated red blood cell counts.
The Challenge of Individualized Care at Scale
Once a TRT protocol is initiated, ongoing monitoring is crucial to ensure treatment efficacy and to detect and manage potential side effects. Current Endocrine Society guidelines recommend against routine population-level screening of asymptomatic men for hypogonadism and advise against routine supplementation for younger men with low testosterone levels, especially when they are not experiencing overt symptoms. These recommendations appear to be at odds with the Department of Defense’s broad screening directive.
Secretary of Defense Pete Hegseth’s statement that it will be up to individual servicemembers to decide whether to take supplements if their testosterone levels are found to be low highlights the necessity of robust patient counseling. This counseling must encompass a detailed discussion of potential risks and benefits, an individualized approach that considers personal preferences and physiology, and critically, personalized monitoring for side effects and treatment response. Implementing such a comprehensive and individualized monitoring system across the entire Department of Defense health system presents a significant logistical and clinical challenge. However, its successful execution is paramount for the safe and responsible implementation of this initiative.
Broader Implications and the Path Forward
The Department of Defense’s decision to implement widespread, mandatory testosterone screening represents a novel approach in population-level health management within a military context. Unlike many other medical screening programs, the implications of identifying and potentially treating low testosterone levels in a young, healthy, and active population are complex and not fully understood. There is no clear precedent for such a large-scale screening and potential treatment initiative for this specific hormonal marker within a uniformed service.
For the well-being of military members, it is imperative that this widespread testing program is accompanied by rigorous, ongoing monitoring at both the individual patient and population levels. This will be critical to ensure that the program is conducted in a safe, effective, and medically appropriate manner, minimizing the potential for unintended negative health consequences. The success of this initiative will hinge on a commitment to evidence-based practice, careful clinical judgment, and a proactive approach to addressing the evolving understanding of testosterone’s role in health and disease.
The Department of Defense has a responsibility to ensure that any health initiative undertaken prioritizes the long-term wellness of its personnel. This requires a balanced perspective, acknowledging both the potential benefits and the significant risks associated with widespread testosterone screening and subsequent treatment. A transparent and data-driven approach, informed by ongoing research and expert medical guidance, will be essential to navigate this unprecedented undertaking.
Alexander Cole, M.D., is a board-certified urologist and health outcomes researcher with extensive experience in men’s health and population-level health initiatives, including within military healthcare systems.
STAT’s coverage of health challenges facing men and boys is supported by Rise Together, a donor advised fund sponsored and administered by National Philanthropic Trust and established by Richard Reeves, founding president of the American Institute for Boys and Men; and by the Boston Foundation. STAT’s financial supporters are not involved in any decisions about its journalism.
